D2B3
New Haven, US · 4 employees on LinkedIn · 1 known investors
D2B3 develops proprietary drug delivery technology that temporarily relaxes the blood-brain barrier to enable therapeutic targeting of central nervous system diseases. The platform is designed to work across multiple drug classes for treating brain-related disorders.
Investors · 1
Frequently asked questions
- What does D2B3 do?
- D2B3 develops proprietary drug delivery technology that temporarily relaxes the blood-brain barrier to enable therapeutic targeting of central nervous system diseases. The platform is designed to work across multiple drug classes for treating brain-related disorders.
- Who are D2B3's investors?
- D2B3's investors include Connecticut Innovations.
- Where is D2B3 headquartered?
- D2B3 is headquartered in New Haven, US.